Quest Diagnostics Q3 2026 slides: 10% revenue growth, raised outlook
Quest Diagnostics (NYSE:DGX) reported Q3 2026 revenue of $3.10B, up 10% YoY, and raised full-year guidance. Adjusted EPS grew 15.4% to $3.00. The company cited strong volume growth and strategic initiatives in Alzheimer's diagnostics and consumer health. Shares rose 0.84% to $240.93, near a 52-week high. Challenges include PAMA reimbursement cuts and Project Nova costs.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise are likely to boost the stock in the short term.
Market read
First report of earnings and guidance raise for a large-cap healthcare company.
What to watch
Potential PAMA reimbursement cuts in 2027 and Project Nova costs could pressure margins.
Background
Quest Diagnostics (DGX) released its Q3 2026 earnings, showing organic growth and raised guidance.
Ticker impact
Quest Diagnostics reported Q3 2026 results with 10% revenue growth and raised full-year guidance.
upside pressure as investors price in higher revenue and EPS outlook
Revenue up 10% YoY and EPS guidance increased to $11.25-$11.35, indicating stronger profitability.
Market effects
Strengthens outlook for the diagnostic services sector, may lift peers.
Positive for US healthcare stocks.
Limited to healthcare investors, no broad macro effect.
Counterpoint
If guidance is overly optimistic, a miss on future quarters could trigger a pullback.
Key entities
- CompanyQuest Diagnostics
Diagnostic testing leader reporting Q3 results.




